DDInter406 DDInter1676
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid].
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Clofazimine {u} (Compound) binds {v} (Gene) ABCB1
Clofazimine {u} (Compound) upregulates {v} (Gene) HERPUD1
Clofazimine {u} (Compound) downregulates {v} (Gene) TUBB6
Clofazimine {u} (Compound) causes {v} (Side Effect) Dermatitis
Clofazimine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clofazimine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Clofazimine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Clofazimine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Clofazimine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Clofazimine (Compound) binds ABCB1 (Gene)
Clofazimine (Compound) upregulates HERPUD1 (Gene)
Clofazimine (Compound) downregulates TUBB6 (Gene)
Clofazimine (Compound) causes Dermatitis (Side Effect)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Clofazimine may lead to a major life threatening interaction when taken with Toremifene
Clofazimine may lead to a major life threatening interaction when taken with Crizotinib